The U.S. Department of Veterans Affairs (VA) has awarded Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, two significant Indefinite Delivery Vehicles (IDVs) to facilitate the procurement of pharmaceutical products. The first is a $15 million Blanket Purchase Agreement (BPA) specifically for the delivery of Jynarque (tolvaptan), a medication used to treat autosomal dominant polycystic kidney disease and hyponatremia. The second is a $396 million Federal Supply Schedule (FSS) contract under the Pharmaceuticals and Drugs schedule, which allows the VA to acquire a wider range of Otsuka's commercial drug offerings, including Jynarque, to support healthcare services for veterans across multiple VA Integrated Service Networks and medical centers.
The majority of task orders issued under these IDVs are for the delivery of Jynarque, typically in 45mg/15mg or 90mg/30mg dosages, to VA facilities nationwide. These firm-fixed price delivery orders, valued between $10,000 and $113,000, do not have any set-aside designations, reflecting Otsuka's status as a large pharmaceutical company. The contracts support the VA's mission to provide specialized treatments and medications to eligible veterans through its integrated healthcare system.
Generated 12/22/24, 12:02 AM